阿霉素异体脱钙骨基质骨粒骨水泥缓释体的制备及相关研究  

The Preparation and Related Study of Decalcified Bone Matrix Particles with Adriamycin Impregnated Bone Cement Drug Sustained Delivery System

作　　者：俞玮[1] 周勇[1] 范清宇[1] 张殿忠[1] 武丽华[2] 

机构地区：[1]第四军医大学唐都医院全军骨科中心,骨肿瘤研究所,西安710038 [2]第四军医大学生化教研室,西安710032

出　　处：《中国矫形外科杂志》2002年第7期685-687,共3页Orthopedic Journal of China

基　　金：第四军医大学创新工程资助项目 (CX99F0 1 2 )

摘　　要：目的 :研制阿霉素异体脱钙骨基质骨粒骨水泥缓释体 ,分析其缓释性能及对骨肉瘤细胞OS - 990 1的抑制能力。方法 :按Urist法制备异体脱钙骨基质骨粒 ,经冻干、真空吸附等处理 ,载入阿霉素与骨水泥按 1∶1复合 ,制得阿霉素异体脱钙骨基质骨粒骨水泥缓释体。对该缓释体行体内外药物释放及其浸出液的体外抑瘤试验。结果 :缓释体体外第 1d释放量为总的 19.2 3% ,其后在较低水平维持相对稳定的缓慢释放 ,持续释放 70d以上 ;其第 1、2 0、4 0、70d的浸出液对骨肉瘤细胞OS - 990 1的抑制率分别为 6 4 .2 7% ,4 1.6 8% ,2 8.71%及 2 4 .32 %。体内释药时 ,局部骨组织浓度高于血浆中浓度 ;局部骨组织早期浓度高 ,以后为稳定的低浓度释放。结论 :该缓释体具有良好的缓释功能 ,在 70d内对骨肉瘤细胞OS - 990 1维持良好有效的抑制率。Objective: To prepare decalcified bone matrix particles (DBMP)with adriamycin impregnated bone cement(BC) drug sustained delivery system (DSDS),it drug delivery characteristic and inhibitory ability on human osteogenic sarcoma cell OS-9901 were analysed.Methods:DBMP were made according to the methods of Urist.Adriamycin was put into DBMP by vacuum absorption and freeze drying techniques.Then the DBMP with adriamycin were impregnated BC mass same ratio and formed DSDS.The release test of DSDS in vitro and vivo and exudant in inhibiting human osteogenic sarcoma cell OS-9901 were examined in vitro.Results:The DSDS have an explosive releasing within the first 24 hours,account for 19.23%.Later it kept slowly stable low drug release and could exist for 60 days.The inhibitory ratio of the first,20th,40 th and 70th day was 64.27%,41.68%,28.71% and 24.32% respectively in vitro.The drug concentrations of local bone tissues were higher than that of plasma;Adriamycin was released with a low drug concentration after 2 days.Conclusions:The DSDS had good sustained release function,it kept excellent inhibitory ratio on human osteogenic sarcoma cell OS-9901 in 70 days.

关 键 词：制备 阿霉素 脱钙骨基质骨粒 骨水泥 缓释体 骨肿瘤 DBMP BC DDS 

分 类 号：R73-36[医药卫生—肿瘤]